{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:53:55Z","timestamp":1760385235819},"reference-count":0,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[1995,11,1]],"date-time":"1995-11-01T00:00:00Z","timestamp":815184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1995,11]]},"abstract":"<jats:p>Five hundred thirty-seven patients were enrolled in two independent, investigator-blinded, multicenter, randomized clinical trials comparing the clinical and bacteriologic efficacies and the safety of 5- or 10-day treatment with cefuroxime axetil with those of 10-day treatment with amoxicillin-clavulanate in the treatment of secondary bacterial infections of acute bronchitis. Patients received either 5 or 10 days of treatment (n = 177 in each group) with cefuroxime axetil at 250 mg twice daily or 10 days of treatment (n = 183) with amoxicillin-clavulanate at 500 mg three times daily. Patients in the cefuroxime axetil (5 days) group received placebo on days 6 to 10. Bacteriologic assessments were based on sputum specimen cultures obtained preceding and, when possible, following treatment. Organisms were isolated from the pretreatment sputum specimens of 242 of 537 (45%) patients, with the primary pathogens being Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Staphylococcus aureus (28, 25, 13, 9, and 8% of isolates, respectively). Pathogens were eradicated or presumed to be eradicated in 87% (52 of 60), 91% (53 of 58), and 86% (60 of 70) of bacteriologically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. A satisfactory clinical outcome (cure or improvement) was achieved in 82% (107 of 130), 86% (117 of 136), and 83% (130 of 157) of the clinically evaluable patients treated with cefuroxime axetil (5 days), cefuroxime axetil (10 days), and amoxicillin-clavulanate, respectively. Treatment with amoxicillin-clavulanate was associated with a significantly higher incidence of drug-related adverse events than was treatment with cefuroxime axetil for either 5 or 10 days (P = 0.001), primarily reflecting a higher incidence of drug-related gastrointestinal adverse events (37 versus 19 and 15%, respectively; P &lt; 0.001), particularly diarrhea and nausea. These results indicate that treatment with cefuroxime axetil at 250 mg twice daily for 5 days is as effective as treatment for 10 days with either the same dose of cefuroxime axetil or amoxicillin-clavulanate at 500 mg three times daily in patients with acute bronchitis. In addition, treatment with cefuroxime axetil for either 5 or 10 days is associated with significantly fewer gastrointestinal adverse events, particularly diarrhea and nausea, than is 10-day treatment with amoxicillin-clavulanate.<\/jats:p>","DOI":"10.1128\/aac.39.11.2528","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:06:25Z","timestamp":1340841985000},"page":"2528-2534","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis"],"prefix":"10.1128","volume":"39","author":[{"given":"D","family":"Henry","sequence":"first","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G E","family":"Ruoff","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Rhudy","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Puopolo","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Drehobl","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Schoenberger","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Giguere","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Collins","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.11.2528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.39.11.2528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:02:20Z","timestamp":1645473740000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.39.11.2528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,11]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1995,11]]}},"alternative-id":["10.1128\/AAC.39.11.2528"],"URL":"https:\/\/doi.org\/10.1128\/aac.39.11.2528","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11]]},"assertion":[{"value":"1995-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}